Warfarin
- Generic Name
- Warfarin
- Brand Names
- Coumadin, Jantoven
- Drug Type
- Small Molecule
- Chemical Formula
- C19H16O4
- CAS Number
- 81-81-2
- Unique Ingredient Identifier
- 5Q7ZVV76EI
- Background
Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ...
- Indication
Indicated for:
1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.
2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.
3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.
...
- Associated Conditions
- Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)
- Associated Therapies
- -
A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin
- Conditions
- Interventions
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 45000
- Registration Number
- NCT05022758
- Locations
- 🇰🇷
Many locations, Multiple Locations, Korea, Republic of
The Safety of Non-vitamin K Oral Anticoagulants Compared to Warfarin Early After Cardiac Surgery
- Conditions
- Interventions
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- St. Paul's Hospital, Canada
- Target Recruit Count
- 100
- Registration Number
- NCT05006287
- Locations
- 🇨🇦
St. Paul's Hospital, Vancouver, British Columbia, Canada
Effect of BIA 5-1058 400 mg on Warfarin Pharmacokinetics
- Conditions
- Interventions
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2021-08-06
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 26
- Registration Number
- NCT04994119
- Locations
- 🇩🇪
PAREXEL International - Early Phase Clinical Unit - Berlin, Berlin, Germany
ALT-801 DDI Study in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2022-12-08
- Lead Sponsor
- Altimmune, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04972396
- Locations
- 🇦🇺
Q-Pharm, Herston, Queensland, Australia
🇦🇺CMAX Clinical Research, Adelaide, South Australia, Australia
Rivaroxaban in Left Ventricular Thrombus
- Conditions
- Interventions
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2024-11-15
- Target Recruit Count
- 261
- Registration Number
- NCT04970576
- Locations
- 🇵🇰
National Institute of Cardiovascular Diseases, Karachi, Sindh, Pakistan
PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates
- Conditions
- Interventions
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04887194
- Locations
- 🇺🇸
Goshen Health, Goshen, Indiana, United States
🇺🇸MultiCare Health System, Tacoma, Washington, United States
🇺🇸NEXT Oncology, Fairfax, Virginia, United States
Replication of the EINSTEIN-PE Anticoagulant Trial in Healthcare Claims Data
- First Posted Date
- 2021-05-10
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 98947
- Registration Number
- NCT04879407
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2021-05-07
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 1000000
- Registration Number
- NCT04878497
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices
- Conditions
- Interventions
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Palak Shah
- Target Recruit Count
- 30
- Registration Number
- NCT04865978
- Locations
- 🇺🇸
Inova Fairfax Medical Campus, Falls Church, Virginia, United States
Anticoagulation Strategies for Acute Venous Thromboembolism in Patients With End-Stage Renal Disease Using USRDS Data
- Conditions
- Interventions
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2021-07-26
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 14914
- Registration Number
- NCT04818151
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.